Generic Fosamax Plus D Availability
FOSAMAX PLUS D (alendronate sodium; cholecalciferol - tablet;oral)
Approval date: April 7, 2005
Strength(s): EQ 70MG BASE;2,800 IU
Approval date: April 26, 2007
Strength(s): EQ 70MG BASE;5,600 IU [RLD]
Has a generic version of Fosamax Plus D been approved?
No. There is currently no therapeutically equivalent version of Fosamax Plus D available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fosamax Plus D. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Method for inhibiting bone resorption
Issued: November 30, 1999
Inventor(s): Daifotis; Anastasia G. & Santora, II; Arthur C. & Yates; A. John
Assignee(s): Merck & Co., Inc.
Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.Patent expiration dates:
- July 17, 2018✓✓
- January 17, 2019✓
- July 17, 2018
More about Fosamax Plus D (alendronate / cholecalciferol)
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|